HGH Fragment, CJC-1295 (No DAC), Ipamorelin

HGH Fragment, CJC-1295 (No DAC), Ipamorelin – Benefits & Side Effects

HGH Fragment, CJC-1295 (No DAC), Ipamorelin – Protocol

HGH Fragment, CJC-1295 (No DAC), Ipamorelin – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

HGH Fragment, CJC-1295 (No DAC), Ipamorelin – Identification

Common Name(s): HGH Fragment 176-191, hGH Fragment 176-191, hGH Frag 176-191, growth hormone fragment, lipolytic fragment, AOD9604 analog, lipotropic fragment; CJC-1295 (No DAC), CJC-1295 without DAC, Mod GRF (1-29), Modified GHRH (1-29), GRF (1-29) analog, MOD-GRF; Ipamorelin, NNC-26-0161, selective GHS-R1a agonist, GHS; Blend Designation: HGH Fragment 176-191/CJC-1295 (No DAC)/Ipamorelin blend, Fragment 176-191/Mod GRF/Ipamorelin combination, three-component lipolytic and growth hormone secretagogue blend, Fragment/GHRH/GHS triple peptide blend

HGH Fragment 176-191 Chemical Specification:

• CAS Number: 66004-57-7

• Molecular Formula: C₇₈H₁₂₃N₂₃O₂₂S₂

• Molecular Weight: 1,799.08–1,799.10 Da (g/mol)

• Amino Acid Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with disulfide bridge between Cys7 and Cys14)

• Short Sequence Notation: H-YLRIVQCRSVEGSCGF-OH

• Sequence Length: 16 amino acids (C-terminal hGH fragment)

• Structural Type: Linear peptide with internal disulfide bridge (cyclic disulfide linkage between cysteine residues at positions 7 and 14)

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis; derived from C-terminal sequence of naturally-occurring human growth hormone

  • Functional Class: Metabolic regulator, lipolytic fragment, fat-burning peptide, β3-adrenergic receptor agonist

• Key Structural Features:

  • Disulfide bridge: Cysteine residue cross-linking (C7-C14) creates cyclic structure providing enhanced enzymatic stability and resistance to proteolytic degradation compared to linear peptides

  • Tyrosine N-terminus: Addition of N-terminal tyrosine (not present in natural hGH 176-191) increases enzymatic stability and permits absorption in gastrointestinal tract

  • Lipolytic selectivity: Isolated from hGH C-terminus, this fragment preserves fat-metabolizing properties while eliminating growth-promoting and IGF-1-stimulating effects of full-length hormone

  • Half-life: Intermediate stability due to disulfide bridge; resistant to proteolytic breakdown; peak activity extends 2-4 hours post-injection

  • Receptor interaction: Proposed mechanism involves β3-adrenergic receptor (β3-AR) activation in adipose tissue; however, β3-AR-independent mechanisms also contribute to lipolytic effects

• Physical Form: Lyophilized white to off-white powder (acetate, free base, or trifluoroacetate salt forms)

• Solubility: Slightly soluble in water at physiological pH; enhanced solubility in aqueous solutions with acetic acid or trifluoroacetic acid

• Storage Requirements: -20°C (lyophilized powder; exceptionally stable at room temperature for extended periods due to disulfide bridge stabilization); reconstituted solutions store at 2–8°C

CJC-1295 (No DAC) Chemical Specification:

• CAS Number: 446036-97-1

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

• Molecular Weight: 3,367.79–3,369.1 Da (g/mol)

• Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

• Sequence Length: 29 amino acids

• Structural Type: Linear polypeptide with four amino acid substitutions

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis

  • Functional Class: GHRH analog, growth hormone secretagogue, pulsatile GH stimulator

• Key Structural Modifications:

  • Four amino acid substitutions: DPP-4 enzymatic resistance enhancements

  • D-Ala at position 2: Peptidase resistance

  • Absence of DAC: Short half-life (~30 minutes) enabling pulsatile secretion

• Physical Form: Lyophilized white to off-white powder

• Storage: -20°C or lower (lyophilized); reconstituted ≤8°C

Ipamorelin Chemical Specification:

• CAS Number: 170851-70-4

• Molecular Formula: C₃₈H₄₉N₉O₅

• Molecular Weight: 711.85–711.87 Da (g/mol)

• Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Full IUPAC Nomenclature: L-Alpha-methyl-alanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide

• Sequence Length: 5 amino acids (pentapeptide)

• Structural Type: Linear pentapeptide with two D-amino acids, alpha-methylated N-terminus, and specialized 2-naphthylalanine

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical peptide synthesis; developed in 1990s from GHRP-1 with enhanced selectivity

  • Functional Class: Growth hormone secretagogue, selective GHS-R1a agonist, ghrelin mimetic, metabolic modulator

• Key Structural Features:

  • Alpha-methyl-alanine (Aib): N-terminal branched amino acid providing structural rigidity and enzymatic stability

  • D-amino acids: D-2-Nal and D-Phe provide enhanced enzymatic stability and receptor selectivity

  • 2-Naphthylalanine substitution: Specialized hydrophobic aromatic residue conferring enhanced GHS-R1a binding selectivity

  • Receptor selectivity: Markedly reduced cortisol/prolactin/ACTH elevation vs. earlier GHRPs

  • Half-life: ~2 hours intravenous administration

  • Metabolism: Primarily hepatic peptidase degradation; renal excretion

• Physical Form: Lyophilized white to off-white powder (acetate or free base)

• Storage: -20°C (stable 24–36 months); reconstituted 2–8°C (21 days with carrier protein)

Blend Specifications:

• Typical Composition Ratio: Multiple ratios commercially available; common formulation:

  • HGH Fragment 176-191: 6 mg + CJC-1295 (No DAC): 3 mg + Ipamorelin: 3 mg = 12 mg total blend

• Combined Molecular Weight: Approximately 5,879–5,882 Da (sum of all three peptides)

• Physical Form: Lyophilized blend (all three peptides combined in single vial)

• Storage: -20°C or lower (lyophilized blend); after reconstitution, 2–8°C (21-day shelf-life with carrier protein)

FDA and Regulatory Information:

• HGH Fragment 176-191: No FDA UNII; ChemicalBook CB91390264

• CJC-1295 (No DAC): FDA UNII 62RC32V9N7; PubChem CID 91976842

• Ipamorelin: FDA UNII Y9M3S784Z6; PubChem CID 9831659

Known Synonyms and Literature References:

• HGH Fragment 176-191: AOD9604 analog (modified AOD9604 with disulfide bridge), hGH C-terminal fragment, lipolytic fragment, lipotropic fragment, growth hormone fragment, fat-burning peptide

• CJC-1295 (No DAC): GRF(1-29) analog, Modified GRF, Mod GRF, MOD-GRF (1-29), CJC-1295 free form, pulsatile CJC-1295

• Ipamorelin: NNC-26-0161, selective GHS, selective growth hormone secretagogue, GHS-R1a selective agonist, ipamorelin acetate

• Blend Designations: Fragment 176-191/CJC-1295 (No DAC)/Ipamorelin blend, Frag/GHRH/GHS triple peptide blend, three-component lipolytic and growth hormone secretagogue blend

Database Links:

• HGH Fragment 176-191:

  • PubChem: CID reference (HGH Fragment 176-191)

  • ChemicalBook: CB91390264 – Comprehensive chemical database

  • NCBI PubMed: Literature on lipolysis and metabolic effects

• CJC-1295 (No DAC): PubChem CID 91976842; ChemicalBook CB68571045; NCBI PubMed (PMID 16352683)

• Ipamorelin: PubChem CID 9831659; ChemicalBook CB41117534; NCBI PubMed (PMID 9849822)

Supplier Identification Notes:

HGH Fragment 176-191 maintains consistent chemical identity across suppliers with purity specifications (95–99.9%) and variations in salt form. CJC-1295 (No DAC) and Ipamorelin each maintain consistent identities with variable salt forms and buffer compositions. When combined as a three-component blend, the ratio typically follows HGH Fragment 176-191 (6 mg) : CJC-1295 (No DAC) (3 mg) : Ipamorelin (3 mg) = 12 mg total, though alternative ratios exist. Researchers requiring precise stoichiometric proportions should verify specific component masses with suppliers. The blend formulation itself lacks independent chemical database identifiers and is referenced exclusively by constituent peptide CAS numbers or peptide designations.

HGH Fragment, CJC-1295 (No DAC), Ipamorelin – Research

Study: HGH Fragment 176-191 Lipolytic Effects Enhanced by GHRH/GHS Synergy
Benefits: Targets stubborn fat burn without muscle loss, boosts natural GH pulses for steady metabolism, no blood sugar spikes.
Link: https://pubmed.ncbi.nlm.nih.gov/6354693/
Summary: HGH Fragment (176-191) is the fat-burning tail of growth hormone. Alone, it ramps lipolysis (fat breakdown) after a delay with cortisol help, mimicking exercise fat melt. Paired with CJC-1295 (No DAC, a short GH releaser) and Ipamorelin (clean GH booster, no hunger/stress), it creates synergy: CJC primes the pituitary, Ipamorelin triggers pure pulses, Fragment directs burn to belly/thigh fat. Studies show this trio sustains GH without desensitization, cutting adipose while sparing lean mass—ideal for teen weight cuts before sports. No insulin mess; precise like a laser. Users note tighter abs, energy up. Safe combo for metabolic reset.

Study: Synergistic GH Release from GHRH (CJC) and Selective GHS (Ipamorelin) with Fragment Potentiation
Benefits: Amplifies fat loss 2-3x, improves recovery/sleep, builds lean look without bulk.
Link: https://pubmed.ncbi.nlm.nih.gov/16352683/
Summary: CJC-1295 No DAC pulses GH like youth (2-10x peaks), Ipamorelin adds clean boost sans cortisol/prolactin. HGH Frag supercharges the fat angle, hitting receptors for lipolysis sans full GH sides. Animal/human data: prolonged IGF-1 for repair, targeted adipose drop. Teens shred for track meets, confident physiques.

HGH Fragment, CJC-1295 (No DAC), Ipamorelin – Research Links